Skip to main content
. 2020 Jun 26;25(Suppl 1):S6–S7. doi: 10.1634/theoncologist.2020-0559

Table 1.

ZUMA‐5: Efficacy endpoints in relapsed/refractory FL and MZL

Endpoint FL (n = 80) MZL (n = 16)
Overall response 95% 81%
Complete response 81% 75%
Partial response 14% 6%
Median DOR 20.8 months 10.6 months
Median PFS 23.5 months 11.8 months
12‐month OS 93.4% 100%

Abbreviations: DOR, duration of response; FL, follicular lymphoma; MZL, marginal zone lymphoma; OS, overall survival; PFS, progression‐free survival.